Veradermics Raises $256M in Upsized IPO, Eyes NYSE Debut

Event summary

  • Veradermics priced its upsized IPO at $17/share, raising $256.3M from 15.08M shares.
  • Shares to begin trading on NYSE under ticker 'MANE' on February 4, 2026.
  • Underwriters granted 30-day option to purchase additional 2.26M shares.
  • Proceeds to support development of dermatology therapeutics, including lead program VDPHL01 for pattern hair loss.

The big picture

Veradermics' $256M IPO underscores investor appetite for late-stage dermatology assets amid a wave of biotech public offerings. The company's focus on high-prevalence conditions like pattern hair loss positions it in a growing segment of aesthetic and medical dermatology. Success will hinge on executing clinical trials while navigating a sector increasingly crowded with competitive therapies.

What we're watching

Clinical Progress
How VDPHL01's development timeline will impact investor confidence post-IPO.
Market Reception
Whether Veradermics can sustain momentum in a competitive dermatology sector.
Execution Risk
The pace at which Veradermics can translate IPO proceeds into pipeline advancements.

Related topics

IPO